Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (13937)	7/3/2000 1:33:28 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Cacaito, reaching $100 million in three years is not, repeat NOT, a spectular event. It has been done by AGN in the past. I thought this would indicate I understood how small the market is for an antiinfective in the opthalmic market. Take a hughe risk trying to get approval, going up against competition and the pay off is $100 million in sales after 5 years? That is not very dramatic and supports what you have posted in the past about this being a small market. Then I pointed out that with nothing in clinic approval will take more time so even assuming success one is looking at many years before one gets to $100 million in sales. Remember I posted some time ago that XOMA share is in the low double digits. I assume 10 or at most 13% royality or share of gross profits. Apparently trying to provide a balanced post no longer works with you. Que passa?